Document Detail

Long-term administration of pegylated recombinant human megakaryocyte growth and development factor dramatically improved cytopenias in a patient with myelodysplastic syndrome.
MedLine Citation:
PMID:  12930386     Owner:  NLM     Status:  MEDLINE    
To date, there are no curative therapeutic options for patients with myelodysplastic syndromes (MDS) other than allogeneic stem cell transplantation. We treated an MDS patient with 10 microg/kg pegylated recombinant human megakaryocyte growth and development factor (rHuMGDF) for more than 450 d. The patient's platelet counts increased from <10 x 10(9)/l to 50 x 10(9)/l. Interestingly, haemoglobin levels increased dramatically and reached over 13 g/dl without additional transfusion. Adverse events and neutralizing antibodies were not observed during treatment, suggesting that the long-term administration of rHuMGDF might be of clinical benefit to patients with MDS.
Masahiro Kizaki; Yoshitaka Miyakawa; Yasuo Ikeda
Related Documents :
15300276 - Pure red cell aplasia in zaria. a 10- year review.
8049856 - Fresh frozen plasma use in a tertiary referral hospital.
19925876 - Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and...
11502666 - Plastic bronchitis and the role of bronchoscopy in the acute chest syndrome of sickle c...
19457826 - Endometriosis of the posterior cul-de-sac: clinical presentation and findings at transv...
16319456 - Trends in incidence of colorectal cancer in jewish and arab populations in central israel.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  British journal of haematology     Volume:  122     ISSN:  0007-1048     ISO Abbreviation:  Br. J. Haematol.     Publication Date:  2003 Sep 
Date Detail:
Created Date:  2003-08-21     Completed Date:  2003-10-27     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  England    
Other Details:
Languages:  eng     Pagination:  764-7     Citation Subset:  IM    
Division of Hematology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bone Marrow Cells / pathology
Hemoglobins / analysis
Myelodysplastic Syndromes / blood,  pathology,  therapy*
Platelet Count
Polyethylene Glycols / therapeutic use*
Recombinant Proteins / therapeutic use*
Thrombopoietin / therapeutic use*
Reg. No./Substance:
0/Hemoglobins; 0/Polyethylene Glycols; 0/Recombinant Proteins; 0/polyethylene glycol-recombinant human megakaryocyte growth and development factor; 9014-42-0/Thrombopoietin
Comment In:
Br J Haematol. 2004 Jun;125(6):818-9   [PMID:  15180875 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Chromosome 11 rearrangements and specific MLL amplification revealed by spectral karyotyping in a pa...
Next Document:  Cutaneous reactions in hairy cell leukaemia treated with 2-chlorodeoxyadenosine and allopurinol.